Clinical Trials · NCT00503399

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
92
Start date
Jul 2007
Locations
13 sites, 4 countries
Primary endpoint
Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months
View Teriparatide compound reference